Chemotherapy in Treating Children With Neuroblastoma

Status Completed

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining buthionine sulfoximine with chemotherapy may reduce resistance to the drug and allow more tumor cells to be killed.

PURPOSE: Phase I trial to study the effectiveness of melphalan, buthionine sulfoximine, and G-CSF in treating children with progressive neuroblastoma that has not responded to previous therapy.

Clinical Trial Description

OBJECTIVES: I. Describe the toxic effects of combined chemotherapy with buthionine sulfoximine (BSO) and melphalan (L-PAM) in pediatric patients with progressive neuroblastoma. II. Determine the pharmacokinetics of BSO/L-PAM in pediatric patients. III. Assess the ability of BSO to deplete glutathione by at least 90% in tumor metastatic to bone marrow, in normal marrow, and in peripheral blood lymphocytes. IV. Estimate the response rate in these patients treated with BSO/L-PAM within the confines of a pilot study.

OUTLINE: The following acronyms are used: BSO Buthionine sulfoximine, NSC-326231 L-PAM Melphalan, NSC-8806 G-CSF Granulocyte Colony-Stimulating Factor, NSC-614629 Single-Agent Chemotherapy with Drug Resistance Inhibition. L-PAM/BSO.

PROJECTED ACCRUAL: At least 18 patients will be entered to provide an adequate number of patients with marrow involvement; if the BSO dose is increased to achieve adequate GSH depletion in the marrow, an additional 12 patients will be entered. If less than 50% of patients have tumor metastatic to marrow at entry, there will be a proportional increase in the total number of patients required. ;

Study Design

Related Conditions & MeSH terms

Neuroblastoma

Clinical Trial Details

NCT number	NCT00002730
Study type	Interventional
Source	Children's Hospital Los Angeles
Contact
Status	Completed
Phase	Phase 1
Start date	June 1996

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00492167` - Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma	Phase 1
Completed	`NCT04474678` - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")	N/A
Terminated	`NCT00801931` - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders	Phase 1/Phase 2
Active, not recruiting	`NCT03107988` - NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)	Phase 1
Recruiting	`NCT04253015` - A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
Terminated	`NCT00788125` - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT02933333` - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Phase 4
Recruiting	`NCT00588068` - Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Recruiting	`NCT04301843` - Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma	Phase 2
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting	`NCT04040088` - An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors	Early Phase 1
Recruiting	`NCT06057948` - A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma	Phase 2
Not yet recruiting	`NCT06335745` - PediCARE Health Equity Intervention in High-Risk Neuroblastoma	N/A
Recruiting	`NCT02559778` - Pediatric Precision Laboratory Advanced Neuroblastoma Therapy	Phase 2
Completed	`NCT02441062` - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT02245997` - Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma	N/A
Not yet recruiting	`NCT01156350` - Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma	Phase 2
Active, not recruiting	`NCT01192555` - Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma	Phase 1/Phase 2
Completed	`NCT01222780` - To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer	Phase 1